Navigation Links
Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
Date:11/6/2008

located on the cell's surface. Once BGC 945 (ONX 0801) enters the cell via this receptor, the compound inhibits, or switches off, thymidylate synthase (TS). BGC 945 (ONX 0801) is distinct from currently marketed TS inhibitors, such as pemetrexed, 5 fluorouracil, and raltitrexed, due to its selective tumor cell-specific uptake by the alpha-folate receptor. The alpha-folate receptor is overexpressed in a number of tumor types with significant unmet needs, including ovarian cancer, lung cancer, breast cancer, and colorectal cancer.

"With its novel mechanism of action, we believe that BGC 945 (ONX 0801) may represent the next era in anti-folate inhibition and has the potential to be the first targeted therapy of its class with greater selectivity for tumor cells over normal cells," said Juergen Lasowski, Ph.D., senior vice president of corporate development at Onyx. "We look forward to advancing BGC 945 (ONX 0801) through the next series of important data-generating milestones."

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding potential clinical applications for BGC 945, the
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
3. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
4. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
6. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
7. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
11. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Nektar Therapeutics (Nasdaq: NKTR ) announced today ... on its board of directors. Winger is ... years of experience in corporate management, financial and ... industry perspective at an important time in the ... CEO of Nektar and member of the Board ...
(Date:12/11/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced ... public offering have exercised in full their option ... stock at the public offering price of $24.75 ... increases the size of the offering to an ... Dendreon expects to receive net proceeds from the ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
(Date:12/10/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today that ... shares of its common stock at a price to ... granted to the underwriters a 30-day option to purchase ... to cover overallotments, if any. The offering is ... customary closing conditions. ,, J. P. Morgan Securities Inc. ...
Breaking Biology Technology:Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3
... March 4 Denis A. Cortese, M.D., president ... vision for personalized healthcare in,America at a time ... the healthcare system. , ... medicine for its,patients. By targeting specific treatments to ...
... Technology to CBI,s DNA Forensic Operations Presented ... Meeting -- Shows ZyGEM,s forensicGEM(TM) DNA Extraction ... Minimize Potential for Contamination and Error -SOLANA ... Va., March 4 ZyGEM Corp. Ltd. ...
... 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... and fiscal year 2008 financial results will be released ... will host a conference call and live webcast at ... company,s financial results and provide a 2009 corporate outlook. ...
Other Biology Technology:Mayo Clinic CEO Offers New Vision for Personalized Patient Care 2Mayo Clinic CEO Offers New Vision for Personalized Patient Care 3Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEM's DNA Extraction Technology 2Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEM's DNA Extraction Technology 3
(Date:12/11/2009)... increases, growers are being challenged to bring consistently ... bottom line, orchard owners are experimenting with new ... labor costs. , Hand thinning, a common practice ... is among the most labor-intensive of orchard practices, ... and, ultimately, prices paid by consumers. A research ...
(Date:12/11/2009)... identify and degrade the diverse types of defective proteins ... researchers Sabine C. Horn, Professor Thomas Sommer, Professor Udo ... Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have now ... enzyme complex that plays a critical role in the ... the identification and disposal of various defectively produced proteins. ...
(Date:12/11/2009)... New discoveries about the deep ocean,s temperature variability and ... conditions. , The deep ocean is affected more by ... for more accurate predictions of factors such as sea ... surface temperatures have also been found to result in ... results in a faster transport of large quantities of ...
Breaking Biology News(10 mins):Horizontal string trimmer reduces labor costs, increases peach size 2MDC researchers identify a scaffold regulating protein disposal 2New discoveries could improve climate projections 2Axsun Technologies A Wholly Owned Subsidiary of Volcano Corporation Announces Breakthrough Integrated Light Source Architecture for Optical Coherenc 6753 1Axsun Technologies A Wholly Owned Subsidiary of Volcano Corporation Announces Breakthrough Integrated Light Source Architecture for Optical Coherenc 6753 2Axsun Technologies A Wholly Owned Subsidiary of Volcano Corporation Announces Breakthrough Integrated Light Source Architecture for Optical Coherenc 6753 3Axsun Technologies A Wholly Owned Subsidiary of Volcano Corporation Announces Breakthrough Integrated Light Source Architecture for Optical Coherenc 6753 4Axsun Technologies A Wholly Owned Subsidiary of Volcano Corporation Announces Breakthrough Integrated Light Source Architecture for Optical Coherenc 6753 5Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced 6750 1Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced 6750 2Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced 6750 3Researchers find increased dairy intake reduces risk of uterine fibroids in black women 62604 1Researchers find increased dairy intake reduces risk of uterine fibroids in black women 62604 2
... Schizophrenia is a developmental disorder with a large genetic ... treat some of the symptoms of schizophrenia, but are ... Unfortunately, it is difficult to predict the effectiveness of ... John H. Krystal, M.D., Editor of Biological Psychiatry ...
... A new scientific review of the most current research ... to be stronger than when the FDA initially approved ... , Dr. James W. Anderson, professor of medicine ... of Medicine, co-authors "The Oatmeal-Cholesterol Connection: 10 Years Later" ...
... Conn., Jan. 7 Accu-Time Systems, Inc., the,leading ... access products, today announced the launch of its ... a member of the,Global Series from ATS., ... that,renders traditional "time clocks" obsolete by removing limitations ...
Other Biology News:Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity 2Oatmeal's health claims strongly reaffirmed, science shows 2Accu-Time Systems, Inc. Announces Launch of Next Generation Human Capital Management (HCM) solutions: Global Series(TM) 2
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
... Rat Antibody to Human CD66 ... is expressed by human neutrophils and ... carcinoma. Clone YTH71.3 reacts with transfectants ... are CEA subfamily members(2). ...
... AFFINITY PURIFIED GOAT ... ANTIBODY is conjugated with ... (RZ>3.0). The antibody ... solid-phase human, rat, fetal ...
Request Info...
Biology Products: